Previous 10 | Next 10 |
2024-04-17 07:23:47 ET More on NovaBay Seeking Alpha’s Quant Rating on NovaBay Historical earnings data for NovaBay Financial information for NovaBay Read the full article on Seeking Alpha For further details see: NovaBay Pharmaceuticals sh...
Growth driven by efficient Avenova ® direct-to-consumer e-marketing programs NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) reports preliminary net revenue for its eyecare and wound care business for the first quarter of 2024 of $2.6 million, a 13% increase ...
2024-03-26 17:03:28 ET More on NovaBay Seeking Alpha’s Quant Rating on NovaBay Historical earnings data for NovaBay Financial information for NovaBay Read the full article on Seeking Alpha For further details see: NovaBay GAAP EPS of -$1.33...
Q4 net sales from the eyecare and wound care segment grew 10% over the prior year with higher sales from the Avenova ® physician dispensed and OTC channels, and from branded wound care products Sales and marketing expenses for the quarter declined 27% reflecting digital marketing...
NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and 12 months ended December 31, 2023 after market close on Tuesday, March 26, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. E...
DERMAdoctor sale reduces operating expenses and bolsters cash NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces that the Company has entered into an agreement to sell its DERMAd...
EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S. Und...
MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- NioBay Metals Inc. (“NioBay” or the “Company”) (TSX-V: NBY) (OTCQB: NBYCF) is pleased to announce the latest results of the fall 2023 drilling campaign, on the Crevier niobium & tantalum project (the “Crevier Proje...
MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) -- NioBay Metals Inc. (“NioBay” or the “Company”) (TSX-V: NBY) (OTCQB: NBYCF) is pleased to announce that, in accordance with the requirements of the TSX Venture Exchange and further to its news release dated February 7, 2024 (e...
MONTREAL, Feb. 07, 2024 (GLOBE NEWSWIRE) -- NioBay Metals Inc. (“NioBay” or the “Company”) (TSX-V: NBY) (OTCQB: NBYCF) is pleased to announce the execution of a definitive option agreement (the “Option Agreement”, the “Option”), with Vior In...
News, Short Squeeze, Breakout and More Instantly...
NovaBay Pharmaceuticals Inc. Company Name:
NBY Stock Symbol:
NYSE Market:
NovaBay Pharmaceuticals Inc. Website:
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) reports record sales of Avenova ® -branded eyecare products during the Amazon Prime Day event, which was held July 16-17, 2024. Over the two-day period, Avenova sales were 17% higher compared with Prime Day 2023 and were up 40% over ...
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company” or “NovaBay”) today announced the closing of its previously announced underwritten public offering of common stock, pre-funded warrants, Series F-1 warrants, Series F-2 warrants and Series F-3 warrants f...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES MONTRÉAL, July 26, 2024 (GLOBE NEWSWIRE) -- NioBay Metals Inc. (“ NioBay ” or the “ Company ”) (TSX-V: NBY) (OTCQB: NBYCF) is pleased to announce th...